Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced an exclusive option and license agreement with SunRock Biopharma (www.sunrockbiopharma.com), a Galician company supported by the regional government, Xunta de Galicia, through Xesgalicia, devoted to the development of antibodies against highly invasive tumors with an urgent clinical need in oncology, for the advancement of the development of specifically targeted antibodies.
The agreement offers Debiopharm licensing options to further develop SunRock’s antibodies integrating Debiopharm’s innovative linker technologies, Multilink™ and AbYlink™, to create innovative antibody drug conjugates (ADCs). Novel ADCs will be developed with capacity to target tumor-specific antigens to fight cancers with high unmet need, including those tumor types expressing HER2/HER3.
ADCs are emerging as promising therapies in the fight against cancer due to their unique ability to target and destroy cancer cells selectively while minimizing damage to healthy tissues. These innovative therapeutics combine the precise targeting capabilities of monoclonal antibodies with the potent cytotoxic effects of small molecule drugs, resulting in a powerful synergistic effect. By harnessing the specificity of antibodies, ADCs can recognize and bind to tumor-specific antigens on the surface of cancer cells, ensuring that the toxic payload is delivered directly to its intended target. This precise approach not only enhances therapeutic efficacy but also reduces systemic toxicity and side effects commonly associated with traditional cancer treatments.
“Our partnership with SunRock could result in the creation of highly innovative antibody-drug conjugates with the potential to tackle cancer in a new way and ultimately improve the lives of cancer patients,” commented Bertrand Ducrey, CEO of Debiopharm. “In a time when few new modalities show promise in effectively beating cancer, the potential of this collaboration is sparking scientific curiosity by combining biology and chemistry.”
Advancements in linker technology have improved ADC stability in circulation, reducing premature drug release and further increasing treatment specificity and effectiveness. Debiopharm’s unique Multilink™ technology can be used to create ADCs that are significantly more effective and better tolerated as it allows the loading of multiple payloads on an antibody. AbYlink™ is an antibody conjugation technology suited to rapidly generate new antibody drug conjugates or imaging antibodies while preserving the original affinity of the antibody to its target.
“We’re highly motivated to uncover the potential of these antibodies with well-validated oncology targets such as HER2 and HER3,” expressed Frederic Levy, Senior Executive Director, Search & Evaluation and Scientific Innovation. “Combining these promising molecules with our linker technology could really boost efficacy and safety to outsmart a wide variety of cancers with a high unmet medical need.”
“We are really enthusiastic about the powerful synergy of SunRock antibodies and bispecific antibodies with Debiopharm’s ADC platform and clinical development capabilities,” commented Laureano Simón, CEO of SunRock Biopharma.
About Multilink™
Multilink™ is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio). This unique and innovative technology allows the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly effective and well-tolerated linker platform is available for use by other specialty biotech or pharmaceutical companies to generate proprietary, clinical-stage ADCs.
About AbYlink™
AbYlink™ is a versatile and rapid antibody conjugation technology for diagnostic purposes and ADC preparation. This site-selective method offers defined and invariable conjugation sites with no impact on antigen-binding regions. It facilitates a seamless, homogenous antibody conjugation process between antibodies and cytotoxic drugs, ensuring optimal stability and controlled drug release at the site of action. AbYlink empowers researchers to design ADCs with enhanced efficacy, safety, and specificity that can address unmet medical needs of patients through cutting-edge ADC innovation.
About SunRock Biopharma
SunRock Biopharma is a biotech company devoted to the development of therapeutic antibodies against highly invasive tumors with an urgent clinical need. SunRock has developed a unique portfolio of first-in-class and best-in-class therapeutic antibodies and bispecific antibodies against novel targets, such as CCR9 and well-known targets such as HER3.
About Debiopharm
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com
Follow us on Twitter @DebiopharmNews at http://twitter.com/DebiopharmNews
Follow us on LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920230991/en/
Contact information
Debiopharm
Dawn Bonine – Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events13.2.2025 11:00:00 EET | Press release
Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/ (Graphic: Xsolla) “This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and creativity and create a channel to bring opportunities together for developers, and we are proud to be a part of this initiative.” Day of the Devs, powered b
Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions13.2.2025 11:00:00 EET | Press release
Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK. The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911. Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science. Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission able to accommodate the additional demands that a turbocharged car places on the drivetrain. Desig
Dreamstime Integrates Fully-Enabled AI Keywording13.2.2025 10:48:00 EET | Press release
Dreamstime introduces its advanced AI keywording tool, enabling fully automated metadata generation. Titles, descriptions, keywords, and categories of stock photos and illustrations are now crafted instantly and directly from an image, streamlining the submission process, saving time for contributors, and enhancing search accuracy for buyers. The newly released feature incorporates Dreamstime’s proprietary AI trained on its own collection of billion images and keywords, building upon the previously introduced keyword suggestion tool. Now enhanced with image recognition, it generates complete metadata, including titles and descriptions, or can provide the location and characteristics of landmarks in photos. The AI-driven suggestions ensure greater accuracy, relevance, and visibility, improving the overall submission and search experiences. Metadata is automatically loaded upon upload, and contributors can accept or refine these suggestions. The agency encourages unique, human-created di
Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”13.2.2025 10:00:00 EET | Press release
At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/ The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire) “In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software
Yamaha Motor: Consolidated Business Results Summary ‐ Full Fiscal Year Ending December 31, 202413.2.2025 03:00:00 EET | Press release
Yamaha Motor Co., Ltd. (Tokyo: 7272) announces its consolidated business results for the full 2024 fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212964437/en/ Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire) Revenues were 2,576.2 billion yen (an increase of 161.4 billion yen or 6.7% compared with the previous fiscal year) due to more unit sales and higher prices per unit for models sold in Brazil and India in our core business of motorcycles. As for operating income, after recording the effects soaring prices had on raising labor costs and other SG&A expenses; expenses linked to conducting reviews of our business structure, such as inventory valuation reductions; and impairment losses on certain fixed assets in the SPV and RV businesses; the final figure for 2024 was 181.5 billion yen (a decrease of 62.4 billion yen or 25.6%). With the decrease in operating income, net income attribut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom